Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2012, Article ID 198313, 8 pages
http://dx.doi.org/10.1155/2012/198313
Review Article

The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Prognostication, Diagnosis, and Management of Thyroid Carcinoma

Division of Endocrine Surgery, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong

Received 22 July 2011; Accepted 15 August 2011

Academic Editor: Yasuhiro Ito

Copyright © 2012 Brian Hung-Hin Lang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Pace, E. Nicolai, M. Klain, and M. Salvatore, “Diagnostic value of FDG PET/CT imaging,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 5, pp. 503–512, 2009. View at Google Scholar
  2. W. Wadsak and M. Mitterhauser, “Basics and principles of radiopharmaceuticals for PET/CT,” European Journal of Radiology, vol. 73, no. 3, pp. 461–469, 2010. View at Publisher · View at Google Scholar · View at PubMed
  3. J. W. Fletcher, B. Djulbegovic, H. P. Soares et al., “Recommendations on the use of 18F-FDG PET in oncology,” Journal of Nuclear Medicine, vol. 49, no. 3, pp. 480–508, 2008. View at Publisher · View at Google Scholar · View at PubMed
  4. A. Newberg, A. Alavi, and M. Reivich, “Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders,” Seminars in Nuclear Medicine, vol. 32, no. 1, pp. 13–34, 2002. View at Google Scholar
  5. B. L. Gerber, F. F. Ordoubadi, W. Wijns et al., “Positron emission tomography using 18F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction,” European Heart Journal, vol. 22, no. 18, pp. 1691–1701, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. H. Joensuu and A. Ahonen, “Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose,” Journal of Nuclear Medicine, vol. 28, no. 5, pp. 910–914, 1987. View at Google Scholar · View at Scopus
  7. B. H. Lang and T. T. Law, “The role of 18F-fluorodeoxyglucose positron emission tomography in thyroid neoplasms,” The Oncologist, vol. 16, no. 4, pp. 458–466, 2011. View at Publisher · View at Google Scholar · View at PubMed
  8. U. Feine, R. Lietzenmayer, J. P. Hanke, H. Wöhrle, and W. Müller-Schauenburg, “18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I,” Nuklearmedizin, vol. 34, no. 4, pp. 127–134, 1995. View at Google Scholar · View at Scopus
  9. H. S. Jeong, C. H. Baek, Y. I. Son et al., “Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT,” Clinical Endocrinology, vol. 65, no. 3, pp. 402–407, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. D. S. Cooper, G. M. Doherty, B. R. Haugen et al., “Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 19, no. 11, pp. 1167–1214, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. D. A. Pryma, H. Schöder, M. Gönen, R. J. Robbins, S. M. Larson, and H. W. D. Yeung, “Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients,” Journal of Nuclear Medicine, vol. 47, no. 8, pp. 1260–1266, 2006. View at Google Scholar · View at Scopus
  12. T. V. Bogsrud, D. Karantanis, M. A. Nathan et al., “18F-FDG PET in the management of patients with anaplastic thyroid carcinoma,” Thyroid, vol. 18, no. 7, pp. 713–719, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. H. S. Jeong, M. Chung, C. H. Baek, Y. H. Ko, J. Y. Choi, and Y. I. Son, “Can [18F]-fluorodeoxyglucose standardized uptake values of PET imaging predict pathologic extrathyroid invasion of thyroid papillary microcarcinomas?” Laryngoscope, vol. 116, no. 12, pp. 2133–2137, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. W. Choi, Y. H. Yoon, Y. H. Yoon, S. M. Kim, and B. S. Koo, “Characteristics of primary thyroid carcinoma with false-negative findings on initial 18F-FDG PET/CT,” Annals of Surgical Oncology, vol. 18, no. 5, pp. 1306–1311, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. M. Yun, T. W. Noh, A. Cho et al., “Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 7, pp. 3182–3188, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. T. T. Law and B. H. H. Lang, “Incidental thyroid carcinoma by FDG-PET/CT: a study of clinicopathological characteristics,” Annals of Surgical Oncology, vol. 18, no. 2, pp. 472–478, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. D. K. Chan, B. H. Lang, and T. T. Law, “Value of fluorodeoxyglucose positron emission tomography in characterizing clinically-significant thyroid carcinomas,” Surgical Practice, vol. 15, no. 2, pp. 34–40, 2011. View at Publisher · View at Google Scholar
  18. D. Esteva, M. A. Muros, J. M. Llamas-Elvira et al., “Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer,” Annals of Surgical Oncology, vol. 16, no. 7, pp. 2006–2013, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. M. Rivera, R. A. Ghossein, H. Schoder, D. Gomez, S. M. Larson, and R. M. Tuttle, “Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma,” Cancer, vol. 113, no. 1, pp. 48–56, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. J. C. Ricarte-Filho, M. Ryder, D. A. Chitale et al., “Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1,” Cancer Research, vol. 69, no. 11, pp. 4885–4893, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. R. J. Robbins, Q. Wan, R. K. Grewal et al., “Real-time prognosis for metastatic thyroid carcinoma based on 2-( 18F)-fluoro-2-deoxy-D-glucose-positron emission tomography scanning,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 2, pp. 498–505, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. D. Deandeis, A. Al Ghuzian, S. Leboulleux et al., “Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptakes) pattern of metastatic thyroid cancer correlate with patient outcome,” Endocrine-Related Cancer, vol. 18, pp. 159–169, 2011. View at Google Scholar
  23. N. Mitsutake, J. A. Knauf, S. Mitsutake, C. Mesa Jr., L. Zhang, and J. A. Fagin, “Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells,” Cancer Research, vol. 65, no. 6, pp. 2465–2473, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. C. Romei, R. Ciampi, P. Faviana et al., “BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer,” Endocrine-Related Cancer, vol. 15, no. 2, pp. 511–520, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. G. Riesco-Eizaguirre, I. Rodríguez, A. De la Vieja et al., “The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer,” Cancer Research, vol. 69, no. 21, pp. 8317–8325, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. C. Durante, E. Puxeddu, E. Ferretti et al., “BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 7, pp. 2840–2843, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. R. Ciampi, A. Vivaldi, C. Romei et al., “Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors,” Molecular and Cellular Endocrinology, vol. 291, no. 1-2, pp. 57–62, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. E. Kresnik, H. J. Gallowitsch, P. Mikosch et al., “Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area,” Surgery, vol. 133, no. 3, pp. 294–299, 2003. View at Publisher · View at Google Scholar · View at PubMed
  29. J. C. Mitchell, F. Grant, A. R. Evenson et al., “Preoperative evaluation of thyroid nodules with 18FDG-PET/CT,” Surgery, vol. 138, no. 6, pp. 1166–1175, 2005. View at Publisher · View at Google Scholar · View at PubMed
  30. L. F. De Geus-Oei, G. F. F. M. Pieters, J. J. Bonenkamp et al., “18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results,” Journal of Nuclear Medicine, vol. 47, no. 5, pp. 770–775, 2006. View at Google Scholar
  31. F. M. Sebastianes, J. J. Cerci, P. H. Zanoni et al., “Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 11, pp. 4485–4488, 2007. View at Publisher · View at Google Scholar · View at PubMed
  32. N. W. Hales, G. A. Krempl, and J. E. Medina, “Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules?” American Journal of Otolaryngology, vol. 29, no. 2, pp. 113–118, 2008. View at Publisher · View at Google Scholar · View at PubMed
  33. R. B. Smith, R. A. Robinson, H. T. Hoffman, and M. M. Graham, “Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid,” Otolaryngology—Head and Neck Surgery, vol. 138, no. 1, pp. 101–106, 2008. View at Publisher · View at Google Scholar · View at PubMed
  34. A. L. Traugott, F. Dehdashti, K. Trinkaus et al., “Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18f-fluorodeoxyglucose positron emission tomography: interim analysis,” World Journal of Surgery, vol. 34, no. 6, pp. 1247–1253, 2010. View at Publisher · View at Google Scholar · View at PubMed
  35. D. Vriens, J. H. de Wilt, G. J. van der Wilt, R. T. Netea-Maier, W. J. Oyen, and L. F. de Geus-Oei, “The role of [(18) F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature,” Cancer. In press. View at Publisher · View at Google Scholar · View at PubMed
  36. B. H. H. Lang and C. Y. Lo, “Technological innovations in surgical approach for thyroid cancer,” Journal of Oncology, vol. 2010, Article ID 490719, 6 pages, 2010. View at Publisher · View at Google Scholar · View at PubMed
  37. A. D. Bloom, L. P. Adler, and J. M. Shuck, “Determination of malignancy of thyroid nodules with positron emission tomography,” Surgery, vol. 114, no. 4, pp. 728–735, 1993. View at Google Scholar
  38. R. D. Utiger, “The multiplicity of thyroid nodules and carcinomas,” The New England Journal of Medicine, vol. 352, no. 23, pp. 2376–2378, 2005. View at Publisher · View at Google Scholar · View at PubMed
  39. J. M. Kim, J. S. Ryu, T. Y. Kim et al., “18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 5, pp. 1630–1634, 2007. View at Publisher · View at Google Scholar · View at PubMed
  40. R. V. Lloyd, L. A. Erickson, M. B. Casey et al., “Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma,” American Journal of Surgical Pathology, vol. 28, no. 10, pp. 1336–1340, 2004. View at Publisher · View at Google Scholar
  41. E. Gemsenjager, A. Perren, B. Seifert, G. Schüler, I. Schweizer, and P. U. Heitz, “Lymph node surgery in papillary thyroid carcinoma,” Journal of the American College of Surgeons, vol. 197, no. 2, pp. 182–190, 2003. View at Publisher · View at Google Scholar · View at PubMed
  42. A. Frilling, K. Tecklenborg, R. Gorges, F. Weber, M. Clausen, and E. C. Broelsch, “Preoperative diagnostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma,” Annals of Surgery, vol. 234, no. 6, pp. 804–811, 2001. View at Publisher · View at Google Scholar
  43. W. Wang, H. Macapinlac, S. M. Larson et al., “[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 7, pp. 2291–2302, 1999. View at Google Scholar
  44. G. Lal, T. Fairchild, J. R. Howe, R. J. Weigel, S. L. Sugg, and Y. Menda, “PET-CT scans in recurrent or persistent differentiated thyroid cancer—is there added utility beyond conventional imaging?” Surgery, vol. 148, no. 6, pp. 1082–1089, 2010. View at Publisher · View at Google Scholar · View at PubMed
  45. T. Petrich, A. R. Borner, D. Otto, M. Hofmann, and W. H. Knapp, “Influence of rhTSH on (18F) fluorodeoxyglucose uptake by differentiated thyroid carcinoma,” European Journal of Nuclear Medicine, vol. 29, no. 5, pp. 641–647, 2002. View at Publisher · View at Google Scholar · View at PubMed
  46. F. Moog, R. Linke, N. Manthey et al., “Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma,” Journal of Nuclear Medicine, vol. 41, no. 12, pp. 1989–1995, 2000. View at Google Scholar
  47. B. B. Chin, P. Patel, C. Cohade, M. Ewertz, R. Wahl, and P. Ladenson, “Recombinant human thyrotrophin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 1, pp. 91–95, 2004. View at Publisher · View at Google Scholar
  48. B. F. Branstetter IV, T. M. Blodgett, L. A. Zimmer et al., “Head and neck malignancy: is PET/CT more accurate than PET or CT alone?” Radiology, vol. 235, no. 2, pp. 580–586, 2005. View at Publisher · View at Google Scholar · View at PubMed
  49. A. Razfar, B. F. Branstetter IV, A. Christopoulos et al., “Clinical usefulness of positron emission tomography—computed tomography in recurrent thyroid carcinoma,” Archives of Otolaryngology—Head and Neck Surgery, vol. 136, no. 2, pp. 120–125, 2010. View at Publisher · View at Google Scholar · View at PubMed